Pathology Research and Practice, volume 263, pages 155590
Detailed pathological role of non-coding RNAs (ncRNAs) in regulating drug resistance of glioblastoma; and update
Foad Rahmanpour Leili
1
,
Niloofar Shali
2
,
Mehrnaz Sheibani
3
,
Mohammad Jafarian
4
,
Fatemeh Pashizeh
5
,
Reza Gerami
6
,
Farideh Iraj
7
,
Afshin Aliporan Lashkarshekan
8
7
Ministry of Health and Treatment, Tehran, Iran. Electronic address: faribaranjipor@gmail.com.
|
Publication type: Journal Article
Publication date: 2024-11-01
Journal:
Pathology Research and Practice
scimago Q2
wos Q2
SJR: 0.677
CiteScore: 5.0
Impact factor: 2.9
ISSN: 03440338, 16180631
Abstract
Glioma is a kind of brain tumor that develops in the central nervous system and is classified based on its histology and molecular genetic features. The lifespan of patients does not exceed 22 months. One of the motives for the low effectiveness of glioma treatment is its radioresistance and chemoresistance. Noncoding RNAs (ncRNAs) are a diverse set of transcripts that do not undergo translation to become proteins in glioma. The ncRNAs have been identified as significant regulators of several biological processes in different cell types and tissues, and their abnormal function has been linked to glioma. They are known to impact important occurrences, including carcinogenesis, progression, and enhanced treatment resistance in glioma cells. The ncRNAs control cell proliferation, migration, epithelial-to-mesenchymal transition (EMT), invasion, and drug resistance in glioma cells. The main focus of this study is to inspect the involvement of ncRNAs in the drug resistance of glioma.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.